Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m |
m |
||
Line 11: | Line 11: | ||
**[[Non-small cell lung cancer, squamous]] | **[[Non-small cell lung cancer, squamous]] | ||
*[[Urothelial carcinoma]] | *[[Urothelial carcinoma]] | ||
− | *[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | + | *[[Malignant solid neoplasm, MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] |
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
Line 35: | Line 35: | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Classical Hodgkin lymphoma medications]] | [[Category:Classical Hodgkin lymphoma medications]] | ||
− | [[Category:MSI-H or dMMR medications]] | + | [[Category:Malignant solid neoplasm, MSI-H or dMMR medications]] |
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] |
Revision as of 23:25, 21 September 2023
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Urothelial carcinoma
- MSI-H or dMMR solid tumors (tissue-agnostic)
History of changes in NMPA indication
- 2019-12-26: Initial approval
- Uncertain date: Full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.
- Uncertain date: Full approval for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy.
- Uncertain date: Full approval for second- or third-line treatment of patients with locally advanced or metastatic NSCLC who progressed on prior platinum-based chemotherapy.
- Uncertain date: Conditional approval for the treatment of patients with classical Hodgkin’s lymphoma (cHL) who received at least two prior therapies
- Uncertain date: Conditional approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- Uncertain date: Conditional approval for the treatment of patients with hepatocellular carcinoma (HCC) who have received at least one systemic therapy
- Uncertain date: Conditional approval for the treatment of patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
Also known as
- Code name: BGB-A317
- Generic name: tilelizumab
- Brand name: Baizean
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal cancer medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Malignant solid neoplasm, MSI-H or dMMR medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Urothelial carcinoma medications
- NMPA approved in 2019